Scholar Rock Holding Corporation (SRRK)

収益の仕組み

Scholar Rock does not yet sell a product, so it has essentially no ongoing revenue: it is funded by cash raised from investors and, in the past, from pharmaceutical partners paying for rights to its science, such as a now-ended collaboration with Gilead. If apitegromab is approved, the company would earn revenue from prescription sales in the US and other markets it can access, but until then its finances are spending, not selling.

主なリスク

• No approved product, no revenue — The company depends entirely on apitegromab and its earlier-stage pipeline succeeding in clinical trials and being approved; failure at any stage leaves it with no product to sell.
• Regulatory approval is not guaranteed — The FDA review process is lengthy and unpredictable, and the company has already had one review cycle for apitegromab complicated by a manufacturing-facility issue rather than the drug itself.
• Clinical trial risk — Proving a drug is safe and effective requires large, expensive trials whose results are inherently uncertain, and a disappointing readout in an ongoing study could stall the whole pipeline.
• Continued need for capital — As a company with no product revenue, Scholar Rock must keep raising cash to fund years of further trials, which can dilute existing shareholders or become harder in a weak market.